In 1990 study in San Diego, CA the 5 dieting active subjects with allergic rhinitis had a lowered tablets total serum IgE from Day 0 to Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, dieting and tablets double-blind, placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. Seven of the 10 active treated subjects had a reduction dieting in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE that stayed the same (plus or minus 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin B12 in lowering tablets serum IgE concentrations.

Jay M. Symptoms not very bad. Karl L. My congestion dieting allergies tablets and dieting and tablets did seem to get better after several days...Marsha R. I had some better days. Erin C. I believe it helped to a certain extent. William R. Improved after 3 days. Nancy C. On day 16 I felt so much better, by day 30 allergies continued to be improved. Angel C. Background of Cyanocobalamin Treatment in Allergic Disease MECHANISM dieting OF ACTION: Vitamin B12 is essential to cell growth and cell division. B12 is the only known molecule in the human body uses with the element cobalt. The tablets unique properties of cobalt permit dieting a chemical reaction that produces the tablets rungs of the DNA ladder. These dieting rungs are called nucleotides. For any human cell to divide, it must copy its own DNA. For this replication tablets to occur, new rungs of the ladder must be provided with the help of B12.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on dieting were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 tablets mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.female-prenatal-supplements.com All rights reserved.